NEW YORK, Jan. 22, 2025 /PRNewswire/ -- According to a new report from global technology intelligence firm ABI Research, 3Q 2024 was a particularly good quarter for nuclear power, with overall investm ...
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA ...